Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Regeneron's score of 54 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Regeneron Pharmaceuticals, Inc. reported total greenhouse gas emissions of approximately 1,465,520,000 kg CO2e. This figure includes Scope 1 emissions of about 80,300,000 kg CO2e, Scope 2 emissions of approximately 40,400,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 1,344,820,000 kg CO2e. The previous year, 2023, saw total emissions of about 972,376,000 kg CO2e, with Scope 1 at 69,600,000 kg CO2e and Scope 2 at approximately 29,900,000 kg CO2e (market-based). Regeneron has set ambitious climate commitments, aiming to reduce its combined Scope 1 and 2 greenhouse gas emissions per square meter by 30% by 2025, using a 2016 peak baseline as the reference point. This target reflects a commitment to improving operational efficiency and reducing carbon intensity. Additionally, the company plans to match 100% of its electricity consumption with certified renewable energy sources by 2035, encompassing both Scope 1 and Scope 2 emissions. The emissions data and reduction targets are sourced directly from Regeneron Pharmaceuticals, Inc., with no cascaded data from parent or related organizations. The company is actively working towards its climate goals, demonstrating a commitment to sustainability and environmental responsibility in the biopharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 39,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 25,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 288,800,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Regeneron has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
